Natco Pharma and Hetero Receives Indian Drug Regulatory Approval for Hepatitis-C Drug

by Reshma Anand on  December 15, 2015 at 12:38 PM Corporate News
RSS Email Print This Page Comment
Font : A-A+

Two Hyderabad-based drug companies, Natco Pharma and Hetero have received approval for the sale of Hepatitis- C drug from the Drugs Controller General of India (DCGI).
Natco Pharma and Hetero Receives Indian Drug Regulatory Approval for Hepatitis-C Drug
Natco Pharma and Hetero Receives Indian Drug Regulatory Approval for Hepatitis-C Drug

The generic version of the drug, Daclatasvir Dihydrochloride (Daclatasvir) is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection.

Natco Pharma will sell the drug under its brand name 'NATDAC' and has received approval for two dosage levels, 60mg and 30 mg. The price is Rs, 6000 for 60mg and Rs. 4000 for 30 mg, for a bottle of 28 tablets.

"It is the first company in India to get approval for generic Daclatasvir Dihydrochloride (Daclatasvir) tablets, 30 mg & 60 mg, from the Drugs Controller General (India)," Natco said.

"Compared with other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patients subsets," Natco added.

Hetero said its product is generic version of Bristol-Myers Squibb's Daklinza tablets.

"The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India," Hetero added.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive